- Trial phase
- Approved
- Time to market
- Already approved and commercially launched in the U.S. (April 2025).
- Why 4/10
- ZEVASKYN is already FDA-approved and commercially launched, so the defining binary catalyst (the approval decision) has passed. There is no pending PDUFA or pivotal readout in the next ~12 months. The next catalysts are commercial execution metrics and the CMS NTAP designation (October 2026), which are not hard binary events. Per the rubric, an approved drug with no pending regulatory decision scores 3-5.
ZEVASKYN is already approved and generating revenue, so the binary approval catalyst is behind it. Watch quarterly commercial metrics (patient starts, revenue growth, treatment center expansion) and the CMS NTAP designation effective October 2026 for reimbursement tailwinds. The stock's ~214% implied upside to the mean analyst target reflects optimism on commercial ramp, but ongoing cash burn and EPS misses warrant caution.
Price Chart
Executive Summary
ZEVASKYN (prademagene zamikeracel, also known as pz-cel) is Abeona Therapeutics' first-in-class autologous cell-sheet gene therapy approved by the FDA on April 28, 2025 for recessive dystrophic epidermolysis bullosa (RDEB), a rare genetic skin disorder. It is the first and only FDA-approved treatment for RDEB. Commercial launch is underway with growing revenue ($11.4M in Q2 2026, up 31% QoQ) and five Qualified Treatment Centers activated. The stock trades at ~$5.42 with a consensus analyst price target of ~$18.86 (214% implied upside), but the company remains unprofitable with widening net losses and no imminent binary catalyst since the approval decision has passed.
How It Works
ZEVASKYN is a personalized gene therapy made from the patient's own skin cells. Doctors take a small sample of the patient's skin, genetically modify the cells in a lab to produce functional type VII collagen (the protein missing in RDEB), grow them into sheets, and surgically graft them onto the patient's wounds. This helps wounds heal and close.
Trial Status
ZEVASKYN was approved by the FDA on April 28, 2025 based on a Phase 3 open-label clinical trial (NCT04227106) that demonstrated durable wound healing. The therapy is now commercially available in the U.S. through a network of Qualified Treatment Centers.
The Two-Sided Case
Upcoming Catalysts
- CMS New Technology Add-on Payment (NTAP) designation effective October 2026, improving hospital reimbursement
- Quarterly earnings reports tracking commercial revenue growth and patient starts
- Expansion of Qualified Treatment Center network beyond current five sites
Source Filing
The SecBot filing or press-release report that triggered this drug report:
ABEONA THERAPEUTICS INC. 8-K ABEO ·Originating report